

Mathilde Jalving

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6770650/mathilde-jalving-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53
papers

1,302
citations

17
h-index

35
g-index

63
ext. papers

1,794
ext. citations

6.8
avg, IF

4.91
L-index

#	Paper	IF	Citations
53	Immune checkpoint inhibitor-associated myocarditis : Case reports and a review of the literature.. <i>Netherlands Heart Journal</i> , 2022 , 1	2.2	2
52	Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancer.. <i>Neuro-Oncology Practice</i> , 2022 , 9, 50-58	2.2	
51	Distinct Genomic Profiles Are Associated with Treatment Response and Survival in Ovarian Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	2
50	Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases.. <i>BMC Cancer</i> , 2022 , 22, 247	4.8	0
49	The gut wall's potential as a partner for precision oncology in immune checkpoint treatment.. <i>Cancer Treatment Reviews</i> , 2022 , 107, 102406	14.4	0
48	Value of screening and follow-up brain MRI scans in patients with metastatic melanoma. <i>Cancer Medicine</i> , 2021 , 10, 8395-8404	4.8	1
47	Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. <i>Annals of Oncology</i> , 2021 ,	10.3	4
46	Postoperative radiotherapy in Merkel cell carcinoma (MCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9575-9575		
45	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2021 , 13,	6.6	1
44	Simultaneous Quantification of the Concentration and Carbon Isotopologue Distribution of Polar Metabolites in a Single Analysis by Gas Chromatography and Mass Spectrometry. <i>Analytical Chemistry</i> , 2021 , 93, 8248-8256	7.8	1
43	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 4369-4376	8.8	4
42	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021 , 151, 72-83	7.5	2
41	Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1498-1510	8.8	2
40	Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients. <i>Onc Immunology</i> , 2021 , 10, 1935104	7.2	0
39	F-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions. <i>Journal of Cancer</i> , 2021 , 12, 562-570	4.5	0
38	COVID-19 vaccination: the VOICE for patients with cancer. <i>Nature Medicine</i> , 2021 , 27, 568-569	50.5	30
37	The Summer School Oncology Groningen: Improving a Successful International Course by Refining the Old, Maintaining What's Good. <i>Journal of Cancer Education</i> , 2021 , 1	1.8	

36	First-in-Human Study of the Biodistribution and Pharmacokinetics of Zr-CX-072, a Novel Immunopet Tracer Based on an Anti-PD-L1 Probody. <i>Clinical Cancer Research</i> , 2021 ,	12.9	3
35	Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores. <i>ESMO Open</i> , 2021 , 6, 100229	6	2
34	Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 1	5.1	1
33	OTHR-01. Unmet clinical needs in patients with brain metastases in the current treatment era. <i>Neuro-Oncology Advances</i> , 2021 , 3, iii14-iii14	0.9	78
32	Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines. <i>Cancer & Metabolism</i> , 2021 , 9, 35	5.4	1
31	F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	6
30	Death Anxiety in Patients With Metastatic Non-Small Cell Lung Cancer With and Without Brain Metastases. <i>Journal of Pain and Symptom Management</i> , 2020 , 60, 422-429.e1	4.8	7
29	Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer. <i>Investigational New Drugs</i> , 2020 , 38, 1454-1462	4.3	4
28	PET segmentation of bulky tumors: Strategies and workflows to improve inter-observer variability. <i>PLoS ONE</i> , 2020 , 15, e0230901	3.7	10
27	HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. <i>Journal of Clinical Investigation</i> , 2020 , 130, 5074-5087	15.9	50
26	Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study. <i>Clinical and Translational Allergy</i> , 2020 , 10, 5	5.2	7
25	The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors. <i>Endocrine-Related Cancer</i> , 2020 , 27, R329-R343	5.7	8
24	Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort 2020 , 8,		7
23	Rational use of F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 153, 103044	7	12
22	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1269-1282	21.7	80
21	Determinants of health-related quality of life in elderly ovarian cancer patients: The role of frailty and dependence. <i>Gynecologic Oncology</i> , 2019 , 153, 610-615	4.9	9
20	Sulfonylurea derivatives and cancer, friend or foe?. <i>European Journal of Pharmacology</i> , 2019 , 861, 172598.3	9.3	11
19	Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. <i>Cancer Letters</i> , 2019 , 461, 102-111	9.9	23

18	NCOG-03. COGNITIVE CONCERNS AND PERFORMANCE IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (mNSCLC). <i>Neuro-Oncology</i> , 2019 , 21, vi159-vi159	1	78
17	Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response. <i>Immuno-Oncology Technology</i> , 2019 , 4, 1-7	2.7	1
16	Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program. <i>Journal of Immunotherapy</i> , 2019 , 42, 208-214	5	6
15	Molecular Imaging in Cancer Drug Development. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 726-732	8.9	29
14	Predictors of adherence to exercise interventions during and after cancer treatment: A systematic review. <i>Psycho-Oncology</i> , 2018 , 27, 713-724	3.9	85
13	A methodology to systematically analyze the hospital discharge of terminally ill patients. <i>Medicine (United States)</i> , 2018 , 97, e12953	1.8	1
12	Preoperative inhibition in patients with irresectable locally advanced stage III melanoma. <i>Melanoma Management</i> , 2018 , 5, MMT08	2.1	0
11	Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative F-FDG PET/CT analysis. <i>EJNMMI Research</i> , 2018 , 8, 101	3.6	18
10	Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer - ESMO-MCBS scores. <i>Cancer Treatment Reviews</i> , 2018 , 69, 233-242	14.4	7
9	Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells. <i>BMC Cancer</i> , 2017 , 17, 232	4.8	28
8	Therapeutic targeting and patient selection for cancers with homologous recombination defects. <i>Expert Opinion on Drug Discovery</i> , 2017 , 12, 565-581	6.2	26
7	Theranostics Using Antibodies and Antibody-Related Therapeutics. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 83S-90S	8.9	75
6	Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 1003-1011	3.5	11
5	Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets. <i>Pharmacology & Therapeutics</i> , 2015 , 147, 63-79	13.9	23
4	Cancer-drug induced insulin resistance: innocent bystander or unusual suspect. <i>Cancer Treatment Reviews</i> , 2015 , 41, 376-84	14.4	36
3	Metformin: taking away the candy for cancer?. <i>European Journal of Cancer</i> , 2010 , 46, 2369-80	7.5	310
2	TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. <i>Clinical Cancer Research</i> , 2006 , 12, 4350-6	12.9	26
1	Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1341-8	6.1	173

